NHS Clinical Commissioners 30 November 2017
Published as Annex D of Item 5 of NHS England Board papers 30 November 2017
- Results of the consultation on proposals to limit the prescription of 18 products which it was felt should not be routinely prescribed in primary care, and around potentially limiting the prescribing of medicines that are available over the counter.
- The basis of the guidance is around low clinical effectiveness (lack of robust evidence of clinical effectiveness or there are significant safety concerns); where more cost effective products are available, and products which are deemed a low priority for NHS funding.
- Consultation resulted in a proposal that NHS England recommends that the Secretary of State formally consider blacklisting the following drugs Co-proxamol, Glucosamine and Chondroitin, Herbal Treatments, Homeopathy, Lutein and Antioxidants, Omega-3 Fatty Acid Compounds and Rubefacients (excluding topical NSAIDS).
- Further consultation will proceed around over the counter products which should not be prescribed in primary care.
